With the focus more on health, and the hopes restrictions can be relaxed because folks are looking after theirs, we examine two stocks getting notice for their efforts to improve our general state.
South San Francisco-based VistaGen Therapeutics (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system diseases and disorders with high unmet medical need.
Tuesday, the company announced plans to expand clinical development of PH94B, its first-in-class rapid-onset neuroactive nasal spray, to include treatment of adjustment disorder due to stressors related to the COVID-19 pandemic.
Adjustment disorder is an emotional or behavioral reaction considered excessive or out of proportion to a stressful event or major life change, occurring within three months of the stressor, and/or significantly impairing a person's social, occupational and/or other important areas of functioning.
VistaGen plans to submit its proposed protocol for a Phase 2 study of PH94B for treatment of adjustment disorder to the U.S. Food and Drug Administration (FDA) through the FDA's new Coronavirus Treatment Acceleration Program.The developments made their presence felt on markets in the last hour of trade, with
VTGN leaping 2.1 cents, or 5.1%, to 44.11 cents, on volume of 2.6 million shares.
Not to be outdone, Delta, B.C.-based Tinkerine Studios Ltd. (TSX-Venture:TTD) obtained the receipt of approval from Health Canada for COVID-19 Medical Device Authorization for Importation or Sale of Class 1 Medical Devices.
This approval was effective Monday, and remains so while the Interim Order is in effect, respecting the importation and sale of medical devices for use in relation to the virus. The approval was bestowed on Tinkerine's wholly-owned subsidiary, Tinkerine 3D Print Systems.
TTD shares rocketed five cents, or 37%, to 18.5 cents, on volume of 5.8 million shares.
